Desmopressin

1. Overview

Desmopressin, chemically 1-desamino-8-D-arginine vasopressin (DDAVP), is a synthetic cyclic nonapeptide analog of the endogenous antidiuretic hormone arginine vasopressin (AVP) [1][2]. Two targeted modifications of the parent hormone define its pharmacology: removal of the primary amino group on the cysteine at position 1 (deamination) and stereochemical inversion of the arginine at position 8 from the L- to the D-form. The deamination protects the molecule from aminopeptidase degradation, while the D-arginine substitution virtually eliminates affinity for V1a receptors on vascular smooth muscle. The result is a molecule with approximately 100-fold selectivity for the V2 receptor over the V1a receptor, producing potent antidiuretic and endothelial hemostatic effects without meaningful vasoconstriction [26][30].

Desmopressin was first synthesized by Ferring Pharmaceuticals in the mid-1960s as part of a structure-activity program aimed at dissociating the antidiuretic and pressor activities of vasopressin. Following its clinical debut as a diagnostic and therapeutic agent for central diabetes insipidus in the early 1970s, Mannucci and colleagues in Milan made the seminal observation in 1977 that intravenous DDAVP produced a 2- to 4-fold rise in circulating factor VIII coagulant activity and von Willebrand factor in patients with mild-to-moderate haemophilia A and von Willebrand disease [1]. This finding opened an entirely new therapeutic domain for the molecule and transformed the management of inherited bleeding disorders by providing the first non-transfusional hemostatic therapy.

Desmopressin was approved by the U.S. Food and Drug Administration (FDA) under the brand name DDAVP in 1978 for the treatment of central diabetes insipidus. Additional FDA approvals followed for primary nocturnal enuresis (1989), mild hemophilia A and type 1 von Willebrand disease under the Stimate brand (intranasal 1.5 mg/mL, 1984), nocturia due to nocturnal polyuria (Noctiva nasal spray, 2017, later commercially withdrawn; Nocdurna orodispersible tablet, 2018), and various other off-label uses in bleeding and hemostasis [20][27][28]. Outside the United States, the molecule is widely distributed under the Minirin brand (oral tablet, intranasal), Octostim (parenteral, Canada and Europe), and numerous generics.

The therapeutic profile of desmopressin thus spans four broad clinical domains, each exploiting V2 receptor biology in a distinct tissue: the renal collecting duct (antidiuresis for diabetes insipidus, enuresis, and nocturia), the vascular endothelium (release of stored factor VIII and von Willebrand factor for hemophilia A, type 1 vWD, uremic bleeding, and perioperative hemostasis), and secondarily the central nervous system (diagnostic applications). This rare combination of distinct, V2R-mediated effects makes desmopressin one of the most versatile peptide drugs in clinical practice.

Molecular Weight

1069.22 g/mol

Sequence

Cyclic nonapeptide: Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 (disulfide Mpa-Cys)

Receptor Selectivity

V2R-selective agonist, approximately 100x vs V1aR

Half-life

1.5-2.5 hours (plasma); antidiuretic effect 6-14 hours

Routes Studied

Intravenous, subcutaneous, intranasal spray/solution, oral tablet, sublingual lyophilisate (melt)

FDA Status

Approved 1978 (DDAVP, central DI); Stimate (hemophilia/vWD, 1984); Minirin; Nocdurna (nocturia ODT, 2018); Noctiva (nocturia nasal spray, 2017; withdrawn 2020)

WADA Status

Prohibited in-competition (masking agent, S5) for some sports; monitored in urine testing

2. Mechanism of Action

Vasopressin Receptor Subtypes and V2 Selectivity

Arginine vasopressin exerts its diverse physiological effects through three G-protein-coupled receptor subtypes: V1a (vascular smooth muscle, hepatocytes, platelets), V1b/V3 (anterior pituitary corticotrophs), and V2 (renal collecting duct principal cells and vascular endothelium) [26]. V1a receptors signal predominantly through Gq/11 and phospholipase C to raise intracellular calcium and mediate vasoconstriction, platelet aggregation, and hepatic glycogenolysis. V2 receptors signal through Gs and adenylyl cyclase to raise intracellular cyclic adenosine monophosphate (cAMP), driving the antidiuretic and endothelial effects that desmopressin exploits.

Native AVP binds V1a and V2 receptors with comparable affinity, producing a mixed vasopressor-antidiuretic profile that limits its therapeutic index for either effect. The chemical modifications in desmopressin strongly shift the binding profile toward V2 [26][30]. Measured EC50 values at the human V2 receptor are in the low nanomolar range, comparable to native AVP, while V1a activity is reduced roughly 100-fold. Clinically, this translates to an antidiuretic effect that is as potent as AVP on a molar basis, but with negligible pressor or uterotonic activity at therapeutic doses.

Renal V2 Receptor Signaling and AQP2 Trafficking

The principal antidiuretic mechanism of desmopressin operates at the basolateral membrane of principal cells in the renal cortical and medullary collecting duct [25]. V2 receptor activation recruits the heterotrimeric Gs protein, activating adenylyl cyclase (predominantly types III and VI in the collecting duct) and raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the water channel aquaporin-2 (AQP2) at several serine residues, most importantly Ser256.

Phosphorylated AQP2 accumulates in subapical storage vesicles and is trafficked to the apical plasma membrane via a kinesin-dependent mechanism. Insertion of AQP2 into the apical membrane dramatically increases transepithelial water permeability, permitting water to flow down the osmotic gradient from the hypotonic tubular fluid into the hypertonic medullary interstitium. Water is then reabsorbed into the vasa recta via constitutively expressed AQP3 and AQP4 on the basolateral membrane. The net result is concentration of urine and retention of free water [25].

This short-term trafficking mechanism drives the rapid antidiuretic effect of desmopressin, which is detectable within 15-30 minutes of intravenous administration and 30-60 minutes of intranasal or oral dosing. With sustained V2 receptor activation, long-term transcriptional effects via cAMP-responsive element-binding protein (CREB) upregulate AQP2 protein abundance, enhancing the maximal concentrating capacity of the kidney over days to weeks.

Endothelial V2 Receptor Signaling: Factor VIII and vWF Release

Desmopressin's hemostatic action is mediated by V2 receptors on vascular endothelial cells, where cAMP-dependent exocytosis releases pre-formed von Willebrand factor (vWF) and the associated factor VIII coagulant activity from Weibel-Palade bodies [2][30]. vWF is a large multimeric glycoprotein synthesized by endothelial cells and megakaryocytes; it serves as the critical plasma chaperone for factor VIII and as the adhesive bridge between platelets and exposed subendothelial collagen.

Following a standard therapeutic dose (0.3 microgram per kilogram intravenously or an intranasal spray of 150-300 micrograms), plasma concentrations of factor VIII and vWF rise 2- to 5-fold above baseline within 30-60 minutes, peak at 60-120 minutes, and return toward baseline over 4-12 hours. The released multimers include ultra-large vWF species that are highly hemostatically active. In patients with mild hemophilia A (baseline factor VIII 5-40 percent), this typically raises factor VIII into a hemostatically adequate range (more than 50 percent) for several hours, supporting minor surgical procedures or treatment of spontaneous bleeds. In type 1 vWD, similar proportional increases in vWF are achieved [1][2][3].

Importantly, the endothelial V2 receptor response is not replicated by V1a-selective agonists such as terlipressin or felypressin, confirming V2 as the hemostatic receptor. Kaufmann and colleagues demonstrated directly in cultured endothelial cells that V2 receptor activation, via cAMP, drives vWF secretion [30].

Tachyphylaxis

A clinically important feature of the endothelial response is rapid tachyphylaxis. Repeated dosing at 12- to 24-hour intervals produces progressively smaller factor VIII and vWF responses, with the second dose typically producing only 70 percent of the initial effect and further attenuation thereafter [4]. The mechanism appears to involve both depletion of the readily releasable endothelial vWF pool (requiring 24-48 hours for replenishment) and some degree of V2 receptor desensitization. This limits desmopressin to at most one to three sequential doses within a 24-48 hour window in bleeding disorders, after which factor concentrate replacement is typically required.

Differential V1/V2 Selectivity and Clinical Consequences

The near-total V2 selectivity of desmopressin has important clinical consequences. Unlike terlipressin (a V1-selective prodrug of lysine vasopressin used for hepatorenal syndrome and variceal bleeding) or felypressin (a V1a agonist used as a local vasoconstrictor in dental anesthesia), desmopressin does not raise blood pressure, does not cause splanchnic vasoconstriction at therapeutic doses, and does not produce uterine contraction. It is therefore contraindicated as a replacement for vasopressin or terlipressin in shock or variceal bleeding, where V1a-mediated vasoconstriction is the sought-after effect.

Conversely, the V2 selectivity makes desmopressin uniquely suitable for chronic antidiuretic therapy. Native AVP infusion for diabetes insipidus produces unacceptable vasopressor effects, whereas desmopressin delivers durable antidiuresis without cardiovascular consequences.

3. Pharmacokinetics

Desmopressin pharmacokinetics vary substantially across formulations, reflecting the challenges of peptide delivery across biological barriers.

Absorption

Intravenous and subcutaneous. Parenteral administration produces essentially 100 percent bioavailability and is the reference standard for pharmacokinetic comparisons. The time to peak concentration is within minutes for IV administration; subcutaneous absorption reaches peak at 40-60 minutes [2]. The intravenous route is used diagnostically (water deprivation test) and in acute hemostatic indications (hemophilia A, type 1 vWD, uremic bleeding, periprocedural bleeding).

Intranasal. The intranasal route (spray or solution) provides bioavailability of approximately 2-4 percent relative to intravenous dosing, with considerable inter-individual variability. Tmax is 40-90 minutes. Two main intranasal products have been marketed: the standard concentration (10 microgram per 0.1 mL spray; DDAVP Nasal Spray, Minirin Nasal Spray) used for diabetes insipidus and enuresis, and the high concentration (1.5 mg/mL; Stimate) used for hemophilia A and vWD, requiring a much higher absolute dose for the hemostatic indication. The low-dose intranasal formulation used for nocturia (Noctiva, 0.83 and 1.66 microgram) employed an emulsion-stabilized carrier (SER-120) to produce modest, controlled antidiuresis with lower peak concentrations than traditional intranasal products.

Oral (tablet). Oral bioavailability is very low, approximately 0.08-0.16 percent, reflecting the susceptibility of the peptide to luminal proteolysis and its limited intrinsic permeability across the enterocyte. Despite the low bioavailability, oral administration of 0.1-0.4 mg produces reliable antidiuretic effects suitable for chronic therapy. Tmax is 1.5-2 hours, and food reduces absorption by approximately 40-50 percent, necessitating fasting administration.

Sublingual lyophilisate (melt/ODT). The orally disintegrating lyophilisate formulation (Minirin Melt, Nocdurna) disintegrates in seconds on the sublingual mucosa, permitting partial absorption across the oral mucosa before swallowing. Bioavailability is approximately 0.25 percent, roughly 60 percent higher than the equivalent oral tablet [14]. This improved bioavailability permits lower absolute doses (for example, 120 or 240 micrograms for enuresis, or 25 and 50 micrograms for nocturia) compared with the tablet. Tmax is 1-2 hours, similar to the tablet.

Distribution

Desmopressin distributes mainly in extracellular fluid, with a volume of distribution of approximately 0.2-0.3 L per kilogram, consistent with limited tissue penetration [26]. It does not cross the blood-brain barrier appreciably, which is clinically relevant because peripheral vasopressin/V2 activity is pharmacologically isolated from central effects.

Metabolism and Elimination

Desmopressin is cleared primarily by renal excretion of unchanged drug and metabolites, with some peptidase-mediated cleavage in kidney and liver. Plasma elimination half-life is 1.5-2.5 hours, but the pharmacodynamic antidiuretic effect persists for 6-14 hours due to slow dissociation from the V2 receptor and sustained AQP2 apical retention [20]. In severe renal impairment (eGFR less than 30 mL per minute per 1.73 m^2), half-life is prolonged and dose reduction is advised; in end-stage renal disease, the drug accumulates and is generally avoided except for single-dose hemostatic use.

Special Populations

Elderly. Plasma clearance is reduced by approximately 30 percent in older adults, and sensitivity to hyponatremia is substantially increased, driving the gender-specific low-dose formulations (25 microgram ODT for women, 50 microgram ODT for men) now standard for nocturia in older adults [10][11][21].

Pediatric. Pharmacokinetics are similar on a weight-adjusted basis, though dose-response for antidiuresis is relatively steeper in younger children, reflecting smaller free-water handling reserves.

Renal impairment. The drug is renally cleared; dose reduction is required in moderate-severe impairment.

Hepatic impairment. No dose adjustment required for mild-moderate hepatic impairment.

4. Researched Applications

Central Diabetes Insipidus (High-Certainty Evidence)

Central diabetes insipidus (CDI) is caused by insufficient posterior pituitary secretion of AVP, typically from neurosurgical trauma, tumors (craniopharyngioma, germinoma, metastases), infiltrative disease, genetic mutations in the AVP gene, or idiopathic causes. The result is inappropriately dilute urine, polyuria (often more than 3 liters per day in adults), polydipsia, and a risk of hypernatremic dehydration if water access is impaired.

Desmopressin is the treatment of choice for CDI [20]. Because it selectively activates the V2 receptor with a therapeutic index markedly greater than native AVP, it permits sustained daily replacement without vasopressor effects. Typical regimens include oral tablets (0.1-1.2 mg per day in divided doses), intranasal spray (2.5-40 microgram per day), or subcutaneous injection for perioperative use (0.5-4 microgram per day).

Diagnostic use during the indirect water deprivation test is well established: after a period of restricted fluid intake produces plasma hyperosmolality, administration of desmopressin should produce at least a 50 percent further increase in urine osmolality in CDI but minimal response in nephrogenic DI, where the V2 receptor-AQP2 pathway is defective at the post-receptor level [15][29]. The 2018 Fenske copeptin study established that measurement of stimulated copeptin during hypertonic saline infusion outperforms the classical indirect water deprivation test for distinguishing CDI from primary polydipsia, though desmopressin challenge remains key to differentiating central from nephrogenic DI [15].

Primary Nocturnal Enuresis (High-Certainty Evidence)

Primary nocturnal enuresis (PNE), or bedwetting, affects approximately 15-20 percent of 5-year-olds and up to 2 percent of adolescents. A subset have documented nocturnal polyuria with blunted overnight AVP secretion, providing a biological rationale for replacement with desmopressin at bedtime.

The Cochrane systematic review first published by Glazener and Evans in 2002 pooled 47 randomized trials of 3448 children and found that desmopressin reduced wet nights per week by approximately 1-2 compared with placebo, with rapid onset of effect but poor durability after treatment cessation [12]. The 2025 update by Hahn and colleagues (16 studies, 1267 participants) confirmed that desmopressin probably increases the number of children achieving 14 consecutive dry nights (RR 3.18; 95% CI 1.75 to 5.80) and may reduce mean wet nights per week by 1.81 nights [13].

The sublingual melt formulation (Minirin Melt, 120-240 microgram at bedtime) has largely supplanted the tablet (0.2-0.6 mg) in pediatric practice. A randomized crossover trial in 221 children demonstrated that the melt achieved significantly greater response rates than equivalent-dose tablet (OR 2.0; 95% CI 1.07 to 3.73), with improved compliance (94.5 vs 88.9 percent) and patient preference, particularly in children under 12 [14].

Clinical practice emphasizes time-limited courses (typically 3-6 months) with scheduled drug holidays to assess natural resolution, minimization of evening fluid intake to reduce hyponatremia risk, and avoidance of intranasal desmopressin for enuresis in children younger than 12 (an FDA safety advisory removed the enuresis indication for the intranasal formulation in 2007 after reports of severe hyponatremia with seizures).

Nocturia due to Nocturnal Polyuria (High-Certainty Evidence)

Nocturia, defined as waking two or more times per night to void, is a common and bothersome symptom in older adults. Nocturnal polyuria (excessive overnight urine production, typically defined as more than 33 percent of 24-hour output occurring during sleep) is the underlying mechanism in a substantial proportion of cases.

The 2017 Cochrane review by Han and colleagues of 14 randomized trials (n = 2242) showed that desmopressin reduced the mean number of nocturic voids per night (mean difference -0.61) and prolonged the first undisturbed sleep interval (mean difference +48 minutes) in men [9]. Parallel trials in women and mixed-sex populations demonstrated comparable benefit, with a notably lower effective dose in women, thought to reflect physiological sex differences in renal sodium handling and V2 receptor density.

Two FDA-approved formulations reached the market specifically for this indication:

• Noctiva (desmopressin acetate nasal spray, 0.83 and 1.66 microgram) was approved in March 2017 based on two Phase 3 trials (n=1045) demonstrating significant reductions in nocturic voids and higher rates of at least 50 percent response versus placebo [8][27]. The formulation used a low-dose spray and was marketed by Serenity Pharmaceuticals. Noctiva carried a boxed warning for hyponatremia and was commercially withdrawn in 2020, reportedly for commercial rather than safety reasons.
• Nocdurna (desmopressin acetate sublingual lyophilisate, 25 microgram for women and 50 microgram for men) was approved in June 2018 based on the Weiss and colleagues trial and pooled analyses by Juul and colleagues demonstrating efficacy with low rates of clinically significant hyponatremia when combined with serum sodium monitoring [10][11][28]. Nocdurna remains commercially available.

The gender-specific dosing (25 microgram for women, 50 microgram for men) is a distinctive feature informed by pooled pharmacodynamic analyses showing greater antidiuretic sensitivity in women at lower doses [11].

Mild Hemophilia A and Type 1 von Willebrand Disease (High-Certainty Evidence)

Mild hemophilia A (baseline factor VIII 5-40 percent) and type 1 von Willebrand disease (reduced but functional vWF) are inherited bleeding disorders in which endogenous factor VIII/vWF stores can be mobilized acutely by V2-mediated endothelial exocytosis. Mannucci's seminal 1977 report established this principle, and 50 years of clinical experience has made desmopressin a cornerstone of hemostatic therapy for these patient populations [1][2][3][23].

A standard test dose of desmopressin (0.3 microgram per kilogram IV) is typically performed at diagnosis to document individual responsiveness, defined as at least a 2-fold rise in factor VIII or vWF to hemostatically adequate levels (more than 50 international units per deciliter). Responders can use desmopressin for minor bleeds, dental procedures, minor surgery, and menstrual bleeding management, often avoiding plasma-derived or recombinant factor concentrates and their attendant risks.

Formulations approved for this indication include:

• DDAVP (intravenous, 4 microgram per mL) at 0.3 microgram per kilogram, diluted in 50 mL saline, infused over 20-30 minutes.
• Stimate (intranasal spray, 1.5 mg per mL) at 150 microgram (1 spray) for patients under 50 kg and 300 microgram (1 spray per nostril) for patients 50 kg or more. The high-concentration spray is 15-fold more concentrated than the standard antidiuretic nasal spray and should not be substituted.
• Subcutaneous 0.3 microgram per kilogram, used where intravenous access is impractical.

Tachyphylaxis limits use to at most two to three consecutive doses within 24-48 hours [4]. Patients with type 2 vWD have variable responses (some subtypes are absolute contraindications due to risk of thrombocytopenia, notably type 2B), and type 3 vWD does not respond because there is essentially no storable vWF to release. A global epidemiological modeling study estimated in 2025 that approximately 40-50 percent of bleeding episodes in eligible patients with type 1 vWD or mild hemophilia A can be managed with desmopressin, representing an important reduction in global factor-concentrate demand [23].

Uremic Bleeding (High-Certainty Evidence)

Patients with advanced chronic kidney disease or acute renal failure frequently develop a qualitative platelet defect that manifests as prolonged bleeding time and increased surgical bleeding, driven partly by uremic toxin interference with platelet-vWF interactions. The Mannucci 1983 NEJM trial demonstrated that intravenous DDAVP (0.3 microgram per kilogram) normalized bleeding time within 1-2 hours in the majority of uremic patients, with effect lasting 4-8 hours [6]. Independent confirmation came from Watson and Keogh in 1982 [7].

DDAVP is now a standard intervention for uremic bleeding, typically used as a single pre-procedural dose or as an adjunct to cryoprecipitate, conjugated estrogens, and correction of anemia. Tachyphylaxis limits repeat dosing.

Periprocedural and Perioperative Hemostasis (Moderate-to-High Evidence)

Desmopressin has been studied extensively for reduction of perioperative blood loss, particularly in cardiac surgery with cardiopulmonary bypass. A 2008 meta-analysis by Crescenzi and colleagues of 18 randomized trials (n=1387) found that desmopressin reduced 24-hour blood loss by approximately 114 mL and red-cell transfusion by 0.29 units compared with placebo, with greatest benefit in patients with identifiable platelet dysfunction or recent aspirin exposure [18]. The 2017 Cochrane review by Desborough and colleagues, encompassing 65 randomized trials and 4143 participants, confirmed modest but clinically relevant reductions in blood loss and transfusion requirements without increasing thrombotic events [19].

More recent meta-analyses including 2024-2025 data have supported a reduction in 24-hour blood loss in cardiac surgery, though effects on major endpoints such as re-exploration or mortality have been inconsistent. Routine prophylactic use is therefore not supported, but desmopressin remains a reasonable consideration in bleeding patients with platelet dysfunction, aspirin/clopidogrel exposure, or vWF-related bleeding diathesis.

Antiplatelet-Associated Intracranial Hemorrhage (Emerging/Mixed Evidence)

An area of active investigation is the use of desmopressin for antiplatelet reversal in spontaneous intracerebral hemorrhage in patients on aspirin or dual antiplatelet therapy. Biological plausibility is supported by the Naidech randomized pilot (n=14) in 2014, which showed DDAVP 0.4 microgram per kilogram IV produced a clinically meaningful improvement in the Verify Now aspirin platelet function assay [17]. However, the 2024 systematic review and meta-analysis by Shahzad and colleagues, pooling 8 studies and 2386 patients, found no significant difference in hematoma expansion, functional outcomes, or thromboembolic events versus controls, with a trend toward increased hyponatremia [16]. American neurocritical care guidelines cautiously suggest consideration of DDAVP 0.4 microgram per kilogram in selected patients while acknowledging the weak evidence base.

Off-Label Uses

Tricyclic antidepressant-induced SIADH. In paradoxical clinical situations involving severe hyponatremia from SIADH or rapid over-correction of chronic hyponatremia, low-dose desmopressin (1-2 microgram IV every 6-8 hours) is used to clamp urinary free-water excretion and prevent osmotic demyelination syndrome. This application exploits the same V2-AQP2 mechanism in a controlled therapeutic manner. Note that this is a specialized hospital-based use and not a general treatment for TCA overdose per se.

Platelet dysfunction from congenital or acquired causes. Desmopressin has been used in platelet storage pool disorders and aspirin-related bleeding, with supportive but limited data.

Preoperative hemostasis in hepatic cirrhosis. The role is uncertain; a trial of desmopressin before minor invasive procedures may be considered in bleeding patients, but evidence for routine use is weak.

Diagnostic testing. Beyond the water deprivation test, desmopressin is used in research protocols to probe endothelial vWF/factor VIII mobilization capacity and in the evaluation of Cushing syndrome (the desmopressin stimulation test of ACTH secretion).

5. Clinical Evidence Summary

6. Dosing in Research and Clinical Use

Desmopressin dosing varies substantially by indication and formulation. The following conventions apply across the therapeutic spectrum.

Central diabetes insipidus. Chronic replacement is typically oral (0.1-1.2 mg per day divided 2-3 times daily), intranasal spray (2.5-40 microgram per day divided 1-3 times daily), or subcutaneous (0.5-4 microgram per day) for perioperative use where oral intake is not reliable. Dosing is titrated to achieve urine output between 1.5 and 3 L per day in adults and to avoid hyponatremia; serum sodium should be checked weekly during initiation and periodically thereafter [20].

Primary nocturnal enuresis. The preferred formulation is sublingual melt (Minirin Melt) at 120-240 microgram at bedtime. Oral tablet (0.2-0.6 mg at bedtime) remains an alternative. Intranasal desmopressin is no longer indicated for enuresis in the United States due to hyponatremia concerns. Treatment is administered for 3-6 months with scheduled drug holidays to assess spontaneous resolution. Evening fluid intake should be restricted to 240 mL from one hour before to 8 hours after dosing [12][13][14].

Nocturia due to nocturnal polyuria (adults). Nocdurna sublingual orodispersible tablet 25 microgram (women) or 50 microgram (men) taken once daily approximately one hour before bedtime is the FDA-approved option [10][11][28]. Serum sodium should be measured before initiation, within 7 days after initiation, and at approximately 1 month, with more frequent monitoring in adults aged 65 and older and in patients on thiazides, SSRIs, or other drugs predisposing to SIADH.

Mild hemophilia A and type 1 vWD. For acute bleeding or periprocedural prophylaxis, intravenous desmopressin 0.3 microgram per kilogram in 50 mL saline infused over 20-30 minutes; alternatively, Stimate intranasal spray 1.5 mg per mL at 150 microgram (patients less than 50 kg) or 300 microgram (patients 50 kg or more); or subcutaneous 0.3 microgram per kilogram. Response should be documented with a test dose (factor VIII and vWF at baseline, 30 minutes, and 2-4 hours). Repeat dosing is limited by tachyphylaxis [1][2][4][5].

Uremic bleeding. Intravenous 0.3 microgram per kilogram over 15-30 minutes, typically as a single pre-procedural dose, with additional supportive measures (correction of anemia, avoidance of NSAIDs, consideration of conjugated estrogens or cryoprecipitate) [6][7].

Cardiac surgery. Intravenous 0.3 microgram per kilogram after protamine reversal, considered for patients with bleeding and documented platelet dysfunction or recent antiplatelet exposure, though not recommended as routine prophylaxis [18][19].

7. Safety and Side Effects

Desmopressin has a well-characterized safety profile after nearly 50 years of clinical use, but the dominant and sometimes severe adverse effect is hyponatremia from unrestricted water intake during antidiuretic therapy [20][21][22].

Hyponatremia and Boxed Warning

All FDA-approved nocturia formulations (Noctiva, Nocdurna) carry a boxed warning stating that desmopressin can cause severe hyponatremia with seizures, coma, respiratory arrest, or death. The risk is particularly high in adults aged 65 and older. Patients aged 65 and older treated with Noctiva had a higher incidence of hyponatremia than younger patients; 16 of 18 subjects with serum sodium of 126-129 mmol per L during the Phase 3 program were in this age group [27].

Pathophysiologically, desmopressin-induced hyponatremia is a dilutional phenomenon: by clamping renal free-water excretion while water intake continues, patients progressively accumulate free water and lower serum osmolality. Severe cases may present with confusion, nausea, headache, seizures, or coma, typically within hours to days of initiation. Risk factors identified across epidemiologic studies include [21][22]:

• Age 65 or older
• Female sex (at equal doses)
• Low baseline serum sodium (less than 135 mmol per L)
• Low body weight
• Concomitant thiazide diuretics
• Concomitant SSRIs, TCAs, NSAIDs, or carbamazepine
• Chronic kidney disease or syndrome of inappropriate antidiuretic hormone secretion (SIADH)
• Heart failure
• Unrestricted evening fluid intake

The 2019 PLOS Medicine population-based cohort study by Fralick and colleagues found that desmopressin users had an adjusted odds ratio for hospitalization for hyponatremia of approximately 19 compared with non-users, underlining the clinical significance of this risk [22]. The 2006 case-series review by Rembratt and colleagues identified similar risk factors and supported mandatory serum sodium monitoring at 7 days and 1 month after initiation [21].

Practical risk mitigation includes using the minimum effective dose (for nocturia, 25 microgram for women and 50 microgram for men), restricting evening fluid intake (maximum 240 mL from 1 hour before dosing to 8 hours after), scheduled serum sodium monitoring, avoiding concomitant drugs that impair free-water excretion, and discontinuing at the first sign of symptomatic hyponatremia. The Vande Walle 30-year safety review found that symptomatic hyponatremia occurred in 0.05-2.5 percent of treated patients across indications, with greatest incidence in older adults and those with risk factors [20].

Cardiovascular Effects

Because of its near-total V2 selectivity, desmopressin at therapeutic doses does not cause clinically meaningful vasoconstriction or hypertension. However, facial flushing, mild headache, and a slight rise in heart rate have been reported, particularly with rapid intravenous administration. Very high doses (greater than 0.4 microgram per kilogram) may produce measurable V1a activation and modest hypertension.

Rapid intravenous administration for hemostatic indications (0.3 microgram per kilogram over less than 10 minutes) has been associated with rare reports of hypotension (probably from reflex vasodilation), tachycardia, and, exceedingly rarely, acute myocardial infarction or thrombotic events in predisposed patients. The 2017 Cochrane perioperative review found no overall increase in thromboembolic events with desmopressin, but caution is advised in patients with coronary artery disease or recent thrombotic events [19].

Volume Expansion

By promoting free-water retention, desmopressin can precipitate fluid overload in patients with heart failure or advanced renal disease. It is relatively contraindicated in decompensated heart failure and severe uncontrolled hypertension.

Gastrointestinal and Local Effects

Common adverse effects include nausea (4-6 percent), abdominal pain, and headache (5-10 percent). Intranasal formulations may produce rhinitis, epistaxis, or nasal irritation. Sublingual formulations are generally well tolerated with rare local effects.

Contraindications and Precautions

Contraindications include known hypersensitivity, moderate-to-severe renal impairment (eGFR less than 30 or 50 mL per minute per 1.73 m^2 depending on formulation), hyponatremia or history of hyponatremia, psychogenic polydipsia, syndrome of inappropriate antidiuretic hormone secretion, and type 2B von Willebrand disease (risk of thrombocytopenia). Desmopressin is generally avoided in decompensated heart failure and is used with caution in patients with a history of thromboembolism.

Drug Interactions

Clinically important interactions include thiazide diuretics and loop diuretics (potentiate hyponatremia risk), SSRIs and SNRIs (additive SIADH-like effect), NSAIDs (reduce renal free-water excretion), carbamazepine and chlorpromazine (potentiate antidiuretic effect), and lamotrigine and lithium (variable effects on water handling). Concomitant use with desmopressin should prompt more intensive sodium monitoring or avoidance.

Pediatric Considerations

In children, desmopressin for enuresis is generally safe but carries the same hyponatremia risk, particularly with concomitant illness, vomiting, or excessive fluid intake. Intranasal desmopressin is no longer recommended for enuresis in the United States following reports of severe hyponatremia and seizures. Evening fluid restriction (no more than 240 mL) is essential [12][13].

8. Comparison with Related Peptides and Historical Context

Desmopressin vs Native Vasopressin

Native arginine vasopressin (AVP) is used clinically as an adjunct vasopressor in septic shock and vasodilatory shock, and historically for diabetes insipidus. AVP has dual V1a and V2 activity, producing vasoconstriction as well as antidiuresis. For sustained V2 effects in outpatient diabetes insipidus, AVP is unsuitable due to its short half-life (minutes) and pressor effects. Desmopressin thus functionally replaces AVP in every outpatient V2-dependent indication.

Desmopressin vs Terlipressin

Terlipressin is a V1a-selective prodrug of lysine vasopressin, used for hepatorenal syndrome type 1 (now FDA-approved as Terlivaz) and for variceal hemorrhage in portal hypertension. Terlipressin produces splanchnic vasoconstriction, reducing portal pressure and improving renal perfusion in hepatorenal syndrome. The V1a-selective pharmacology is opposite to that of desmopressin, and the two agents are not interchangeable. Desmopressin does not treat hepatorenal syndrome or variceal bleeding; terlipressin does not treat diabetes insipidus or hemophilia.

Desmopressin vs Felypressin

Felypressin (2-phenylalanine-8-lysine vasopressin) is a V1a-selective agonist used as a local vasoconstrictor in dental local anesthetic formulations, providing prolonged anesthetic duration without systemic sympathomimetic effects. Its selectivity profile is again opposite to desmopressin.

Desmopressin vs Oxytocin

Oxytocin is structurally similar to AVP (nine amino acids, one disulfide bridge) and acts on the oxytocin receptor (OXTR) in uterine smooth muscle and mammary myoepithelium. Despite the structural similarity, desmopressin's modifications produce minimal cross-reactivity with OXTR, and desmopressin does not produce uterine contraction at therapeutic doses. Oxytocin and desmopressin are both cyclic nonapeptides derived from the same ancestral family but serve entirely distinct clinical roles. See the oxytocin and vasopressin monographs for detailed comparisons.

Historical Milestones

• 1895: Oliver and Schafer describe the pressor effects of posterior pituitary extract.
• 1953-1954: du Vigneaud synthesizes oxytocin and vasopressin; receives Nobel Prize 1955.
• 1967-1968: Ferring synthesizes DDAVP and demonstrates V2 selectivity in animal studies.
• 1977: Mannucci and colleagues report factor VIII/vWF release after IV DDAVP in haemophilia A and vWD [1].
• 1978: FDA approves DDAVP for central diabetes insipidus.
• 1983: Mannucci et al. publish the landmark NEJM study of DDAVP in uremic bleeding [6].
• 1984: Stimate (intranasal 1.5 mg/mL) approved for hemophilia A and vWD.
• 1988: Mannucci's seminal Blood review consolidates the hematologic applications [2].
• 1989: DDAVP approved for primary nocturnal enuresis in children.
• 2007: FDA advisory removes intranasal DDAVP enuresis indication after hyponatremia reports.
• 2017: Noctiva (low-dose nasal spray) approved for nocturia; commercially withdrawn in 2020.
• 2018: Nocdurna (sublingual ODT, 25/50 microgram) approved for nocturia with gender-specific dosing.
• 2025: Updated Cochrane review on enuresis (Hahn et al.) reconfirms benefit in children [13].
• 2025-2026: Ongoing global hemophilia care initiatives emphasize desmopressin's role in reducing factor-concentrate dependence in eligible patients [23].

9. Regulatory Status

United States (FDA). Desmopressin was first approved in 1978 as DDAVP (intranasal solution, later also tablet and injection) for central diabetes insipidus and hemophilia A/vWD. Stimate (intranasal 1.5 mg/mL) was approved in 1984 for mild hemophilia A and type 1 vWD. Intranasal DDAVP was approved for primary nocturnal enuresis in 1989, but the enuresis indication for the intranasal formulation was removed in 2007 due to reports of severe hyponatremia with seizures. Noctiva (desmopressin acetate nasal spray, 0.83 and 1.66 microgram) was approved in March 2017 for nocturia due to nocturnal polyuria, with a boxed warning for hyponatremia; the product was commercially withdrawn in 2020 for business reasons unrelated to safety or efficacy [27]. Nocdurna (desmopressin acetate sublingual 25 and 50 microgram) was approved in June 2018 for nocturia and remains available [28].

European Union and international. Desmopressin is available worldwide under multiple brand names including Minirin (oral, intranasal; diabetes insipidus, enuresis), Octostim (parenteral; hemostasis), Nocutil, and Noqdirna (orodispersible; nocturia). Regulatory indications closely parallel those in the United States, with some variation in pediatric dosing and intranasal enuresis use.

Sports (WADA). Desmopressin is listed by the World Anti-Doping Agency as a prohibited substance in specific sports or contexts because it can expand plasma volume and act as a masking agent for urine dilution-based tests. Athletes should be aware that therapeutic use requires a Therapeutic Use Exemption (TUE) for relevant indications.

10. Related Peptides

See also: Vasopressin (AVP), Oxytocin

11. References

1. [1] Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. (1977). 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet. DOI PubMed
2. [2] Mannucci PM. (1988). Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood. DOI PubMed
3. [3] Mannucci PM. (1997). Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood. DOI PubMed
4. [4] Mannucci PM, Bettega D, Cattaneo M. (1992). Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). British Journal of Haematology. DOI PubMed
5. [5] Rose EH, Aledort LM. (1991). Nasal Spray Desmopressin (DDAVP) for Mild Hemophilia A and von Willebrand Disease. Annals of Internal Medicine. DOI PubMed
6. [6] Mannucci PM, Remuzzi G, Pusineri F, et al. (1983). Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. New England Journal of Medicine. DOI PubMed
7. [7] Watson AJ, Keogh JA. (1982). Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron. DOI PubMed
8. [8] Weinberg AC, Tenggardjaja CF, Moldwin RM. (2017). Desmopressin acetate nasal spray for adults with nocturia. Expert Review of Clinical Pharmacology. DOI PubMed
9. [9] Han J, Jung JH, Bakker CJ, et al. (2017). Desmopressin for treating nocturia in men. Cochrane Database of Systematic Reviews. DOI PubMed
10. [10] Weiss JP, Herschorn S, Albrecht D, Radomski SB. (2012). Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. Journal of Urology. DOI PubMed
11. [11] Juul KV, Klein BM, Norgaard JP. (2013). Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourology and Urodynamics. DOI PubMed
12. [12] Glazener CM, Evans JH. (2002). Desmopressin for nocturnal enuresis in children. Cochrane Database of Systematic Reviews. DOI PubMed
13. [13] Hahn D, Stewart F, Raman G, et al. (2025). Desmopressin for nocturnal enuresis in children (updated Cochrane review). Cochrane Database of Systematic Reviews. DOI PubMed
14. [14] De Guchtenaere A, Van Herzeele C, Raes A, et al. (2013). Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. European Journal of Pediatrics. DOI PubMed
15. [15] Fenske W, Refardt J, Chifu I, et al. (2018). A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. New England Journal of Medicine. DOI PubMed
16. [16] Shahzad M, Mustafa K, Ahmad F, et al. (2024). Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: A systematic review and meta-analysis. Brain and Behavior. DOI PubMed
17. [17] Naidech AM, Maas MB, Levasseur-Franklin KE, et al. (2014). Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke. DOI PubMed
18. [18] Crescenzi G, Landoni G, Biondi-Zoccai G, et al. (2008). Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology. DOI PubMed
19. [19] Desborough MJR, Oakland K, Brierley CK, et al. (2017). Desmopressin use for minimising perioperative blood transfusion. Cochrane Database of Systematic Reviews. DOI PubMed
20. [20] Vande Walle J, Stockner M, Raes A, Norgaard JP. (2008). Desmopressin 30 years in clinical use: a safety review. Current Drug Safety. DOI PubMed
21. [21] Rembratt A, Riis A, Norgaard JP. (2006). Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourology and Urodynamics. DOI PubMed
22. [22] Fralick M, Schneeweiss S, Wallis CJD, et al. (2019). Desmopressin and the risk of hyponatremia: A population-based cohort study. PLOS Medicine. DOI PubMed
23. [23] Trillo L, Schollhammer M, Garde C, et al. (2025). Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A. Haemophilia. DOI PubMed
24. [24] Cawley MJ, Flaherty T, Dickerson G, et al. (2024). Desmopressin (DDAVP): Review of the 50-year path to approved use in von Willebrand disease, hemophilia A, diabetes insipidus, and nocturnal enuresis. StatPearls. PubMed
25. [25] Nielsen S, Frokiaer J, Marples D, et al. (2002). Aquaporins in the kidney: from molecules to medicine. Physiological Reviews. DOI PubMed
26. [26] Juul KV, Bichet DG, Nielsen S, Norgaard JP. (2014). The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. American Journal of Physiology - Renal Physiology. DOI PubMed
27. [27] FDA. (2017). NOCTIVA (desmopressin acetate) nasal spray prescribing information. FDA Label Documents.
28. [28] FDA. (2018). NOCDURNA (desmopressin acetate) sublingual tablet prescribing information. FDA Label Documents.
29. [29] Bichet DG. (1998). Nephrogenic diabetes insipidus. American Journal of Medicine. DOI PubMed
30. [30] Kaufmann JE, Oksche A, Wollheim CB, et al. (2000). Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. Journal of Clinical Investigation. DOI PubMed